Lemang Bio Raises 200M RMB for AI CAR-T
Lemang Bio secured nearly 200M RMB in funding led by Yuecai Zhongyin and XtalPi to advance low-dose metabolic enhanced CAR-T clinical trials and production. The META 10 and META 10-AI platforms enable T-cell metabolic reprogramming for superior efficacy at ultra-low doses. Key progress includes CD19 CAR-T IND filing and IIT results showing 100% CR in B-ALL.






